Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bakuchiol + ethyl linoleate is a topical combination of two natural ingredients, bakuchiol (a plant-derived functional analog of retinol) and ethyl linoleate (a fatty acid ester), developed for skincare applications. This combination exerts synergistic effects in keratinocytes by **inhibiting fatty acid binding protein 5 (FABP5)** and **fatty acid amide hydrolase (FAAH)**, resulting in increased levels of endocannabinoid (eCB) ligands (such as AEA, 2-AG, OEA, and PEA). This leads to enhanced activation of cannabinoid receptors (CB1, CB2) and TRPV1, with downstream suppression of inflammatory pathways (reduction of TNF, COX-2, type I interferon gene expression), reversal of TNF-induced gene shifts, and inhibition of cortisol secretion. Bakuchiol + ethyl linoleate also upregulates genes linked to cell proliferation and stemness while repressing those for keratinocyte differentiation. The formulation is primarily intended as an **innovative topical agent for managing inflammatory and compromised skin conditions** such as acne and atopic dermatitis. It is marketed by Sytheon under the brand name Asyntra D-Stress[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bakuchiol + ethyl linoleate.